Skip to main content
Article thumbnail
Location of Repository

Dietary Modulation of Inflammation-Induced Colorectal Cancer through PPARγ

By Ashlee B. Carter, Sarah A. Misyak, Raquel Hontecillas and Josep Bassaganya-Riera


Mounting evidence suggests that the risk of developing colorectal cancer (CRC) is dramatically increased for patients with chronic inflammatory diseases. For instance, patients with Crohn's Disease (CD) or Ulcerative Colitis (UC) have a 12–20% increased risk for developing CRC. Preventive strategies utilizing nontoxic natural compounds that modulate immune responses could be successful in the suppression of inflammation-driven colorectal cancer in high-risk groups. The increase of peroxisome proliferator-activated receptor-γ (PPAR-γ) expression and its transcriptional activity has been identified as a target for anti-inflammatory efforts, and the suppression of inflammation-driven colon cancer. PPARγ down-modulates inflammation and elicits antiproliferative and proapoptotic actions in epithelial cells. All of which may decrease the risk for inflammation-induced CRC. This review will focus on the use of orally active, naturally occurring chemopreventive approaches against inflammation-induced CRC that target PPARγ and therefore down-modulate inflammation

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2007). 4-Hydroxynonenal and PPARγ ligands affect proliferation, differentiation, and apoptosis in colon cancer cells,”
    2. (2008). A 9-cisβ-caroteneenriched diet inhibits atherogenesis and fatty liver formation
    3. (2004). A CLA’s act: feeding away inflammation,”
    4. (2002). a n ,P .C .I p ,a n d
    5. (1999). A novel therapy for colitis utilizingPPAR-γ ligandstoinhibittheepithelialinflammatory response,”
    6. (1999). a r r a f ,E .M u e l l e r ,W .M .S m i t h ,e ta l . ,“ L o s s - o f - f u n c t i o n mutations in PPARγ associated with human colon cancer,”
    7. (2005). A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-γ,”
    8. (2007). Activation of peroxisome proliferator-activated receptor γ inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer,”
    9. (2004). Activation of PPAR γ and Δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease,”
    10. (1998). Activators of the nuclear receptor PPARγ enhance colon polyp formation,”
    11. (1998). andA.Gil,“Dietarymonounsaturatedn-3andn-6long-chain polyunsaturated fatty acids affect cellular antioxidant defense system in rats with experimental ulcerative colitis induced byPPAR
    12. (2008). B.A.Miller,K.C.Chu,B.F.Hankey,andL.A.G.Ries,“Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in
    13. (2008). Blocking TNFα in mice reduces colorectal carcinogenesis associated with chronic colitis,”
    14. (2003). C a m p b e l l ,W .L .S t o n e ,S .G .W h a l e y ,M .Q u i ,a n dK . Krishnan, “Gamma (γ) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (γ) expression in SW 480 human colon cancer cell lines,”
    15. (2006). Cancer epidemiology in older adolescents and young adults 15 to 29 years of age,”
    16. (2008). Cancer in inflammatory bowel disease,”
    17. (2007). Cancer prevention by dietary bioactive components that target the immune response,”
    18. (2007). Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells,”
    19. (2008). Circulating levels of inflammatory cytokines and risk of colorectal adenomas,”
    20. (2006). CLA and n-3 PUFA differentially modulate clinical activity and colonic PPARresponsive gene expression in a pig model of experimental
    21. (2008). Colorectal cancer and dysplasia in inflammatory bowel disease,”
    22. (2005). Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences,”
    23. (2008). Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFκB,” Carcinogenesis,
    24. (2008). Curcumin: from ancient medicine to current clinical trials,”
    25. (2003). Development of gamma (γ)-tocopherol as a colorectal cancer chemopreventive agent,”
    26. (2008). DHA induces ER stress and growth arrest in human colon cancer cells: associations with cholesterol and calcium homeostasis,”
    27. (2007). Dietary fiber and whole-grain consumption in relation to colorectal cancer in
    28. (2006). Dietary phytoestrogen intake is associated with reduced colorectal cancer risk,”
    29. (2004). e l l y ,J .I .C a m p b e l l ,T .P .K i n g ,e ta l . ,“ C o m m e n s a l anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shutting of PPAR-γ and
    30. (2006). F u n k ,J .B .F r y e ,J .N .O y a r z o ,e ta l . ,“ E fficacy and mechanism of action of turmeric supplements in the treatment of experimental arthritis,”
    31. (2009). F4/80hiCCR2hi macrophage infiltration into the intraabdominal fat worsens the severity of experimental
    32. (1995). Folic acid as a cancer-preventing agent,”
    33. (2007). Gender disparity in liver cancer due to sex differences
    34. (2009). Getting the bugs out of the immune system: do bacterial microbiota “fix”
    35. (2008). Growth inhibition of human colon cancer cells by plant compounds,”
    36. (2005). Hic-5 regulates an epithelial program mediated by PPARγ,”
    37. (2006). How many drug targets are there?”
    38. (2004). IKKβ links inflammation and tumorigenesis in a mouse model of colitisassociated cancer,”
    39. (2008). Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies,”
    40. (2008). In vitro effects of tea polyphenols on redox metabolism, oxidative stress, and apoptosis
    41. (2004). Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cancer cell lines by troglitazone,”
    42. (2006). Inflammation and insulin resistance,”
    43. (2007). Innate immune system regulation of nuclear hormone receptors in metabolic diseases,”
    44. (2006). J.A.Read,S.T.B.Choy,P.J.Beale,andS.J.Clarke,“Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival,”
    45. (2008). Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis,”
    46. (2000). Mechanisms for the impact of whole grain foods on cancer risk,”
    47. (1977). Microbial ecology of the gastrointestinal tract,”
    48. (2008). Multi-targeted therapy of cancer by omega-3 fatty acids,”
    49. (2008). Multitargeted cancer prevention by quercetin,”
    50. (2008). NF-κB and cancer—identifying targets and mechanisms,”
    51. (2001). Nuclear receptor minireview series,”
    52. (2008). Omega-3 fatty acids and PPARγ in cancer,”
    53. On the origin of cancer cells,”
    54. (2009). Oral administration of blueberry inhibits angiogenic tumor growth and enhances survival of mice with endothelial cell neoplasm,” Antioxidants and Redox Signaling,
    55. (2008). Oxidative stress in ulcerative colitis-associated carcinogenesis,”
    56. (2000). Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB,”
    57. (2003). P.Munkholm,“Reviewarticle:theincidenceandprevalenceof colorectal cancer in inflammatory bowel disease,”
    58. (1999). Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction,”
    59. (1999). Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells,”
    60. (2007). Peroxisome proliferator-activated receptor γ (PPARγ) and colorectal carcinogenesis,”
    61. (2003). Peroxisome proliferator-activated receptor γ and cancers,”
    62. (2006). Pioglitazone, a synthetic ligand for PPARγ, induces apoptosis in RB-deficient human colorectal cancer cells,”
    63. (2005). PPARs in diseases: control mechanisms of inflammation,”
    64. (2007). PPARγ in immunity and inflammation: cell types and diseases,”
    65. (2007). PPARγ physiology and pathology in gastrointestinal epithelial cells,”
    66. (2007). R a m a k e r s ,M .I .V e r s t e g e ,G .T h u i j l s
    67. (1932). Regional ileitis, a pathologic and clinical entity,”
    68. (2007). Regulation of spontaneous intestinal tumorigenesis through the adaptor protein
    69. (2006). Resveratrol improves health and survival of mice on a high-calorie diet,”
    70. (2006). Review article: mode of action and delivery of 5-aminosalicylic acid—new evidence,”
    71. (2008). Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies,”
    72. (1905). Role of nutrition in preventing cancer,”
    73. (2008). Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer,”
    74. (2009). Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumorderived endothelial cells and tumor angiogenesis in vivo,”
    75. (2004). ROS stress in cancer cells and therapeutic implications,”
    76. (1992). Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma,”
    77. (2008). State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in
    78. (2008). Sumoylation of peroxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cytokines,”
    79. (2005). T lymphocyte numbersinhumangutassociatedlymphoidtissuearereduced without enteral nutrition,” J o u r n a lo fP a r e n t e r a la n dE n t e r a l Nutrition,
    80. (2007). The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults,” Diabetes Care,
    81. (2003). The two faces of IKK and NF-κB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion,”
    82. (2008). Thiazolidinediones as anti-cancer agents,”
    83. (2006). TNF-α in promotion and progression of cancer,”
    84. (2008). u r p h y ,P .T r a v e r s ,a n dM .W a l p o r t ,Janeway’s Immunobiology,
    85. (2008). Upregulation of annexin A1 expression by butyrate in human colon adenocarcinoma cells: role of
    86. (2004). Whaley,andH.Yang,“Tocopherolsandthetreatmentofcolon cancer,”
    87. (2004). Y .W .Chan,etal.,“Effectofperoxisome proliferator activated receptor γ ligands on growth and gene expression profiles of gastric cancer cells,”

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.